Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 183

1.

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline Summary.

Shapiro CL, Lacchetti C, Neuner J.

J Oncol Pract. 2019 Sep 24:JOP1900427. doi: 10.1200/JOP.19.00427. [Epub ahead of print] No abstract available.

PMID:
31550200
2.

Management of Osteoporosis in Survivors of Adult Cancers With Nonmetastatic Disease: ASCO Clinical Practice Guideline.

Shapiro CL, Van Poznak C, Lacchetti C, Kirshner J, Eastell R, Gagel R, Smith S, Edwards BJ, Frank E, Lyman GH, Smith MR, Mhaskar R, Henderson T, Neuner J.

J Clin Oncol. 2019 Sep 18:JCO1901696. doi: 10.1200/JCO.19.01696. [Epub ahead of print]

PMID:
31532726
3.

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline Summary.

Shapiro CL, Yarom N, Peterson DE, Bohlke K, Saunders DP.

J Oncol Pract. 2019 Aug 26:JOP1900384. doi: 10.1200/JOP.19.00384. [Epub ahead of print] No abstract available.

PMID:
31449435
4.

De-escalation yes, but not at the expense of efficacy: in defense of better treatment.

Shapiro CL.

NPJ Breast Cancer. 2019 Aug 12;5:25. doi: 10.1038/s41523-019-0120-z. eCollection 2019. No abstract available.

5.

Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline.

Yarom N, Shapiro CL, Peterson DE, Van Poznak CH, Bohlke K, Ruggiero SL, Migliorati CA, Khan A, Morrison A, Anderson H, Murphy BA, Alston-Johnson D, Mendes RA, Beadle BM, Jensen SB, Saunders DP.

J Clin Oncol. 2019 Sep 1;37(25):2270-2290. doi: 10.1200/JCO.19.01186. Epub 2019 Jul 22.

PMID:
31329513
6.

Early Detection of Anthracycline-Induced Cardiotoxicity in Breast Cancer Survivors With T2 Cardiac Magnetic Resonance.

Lustberg MB, Reinbolt R, Addison D, Ruppert AS, Moore S, Carothers S, Suresh A, Das H, Berger M, Ramaswamy B, Wesolowski R, Binkley P, Raman SV, Shapiro CL.

Circ Cardiovasc Imaging. 2019 May;12(5):e008777. doi: 10.1161/CIRCIMAGING.118.008777. No abstract available.

PMID:
31060375
7.

Central nervous system metastases in triple-negative breast cancer: A step in the right direction.

Shreenivas A, Shapiro CL.

Breast J. 2019 May;25(3):361-362. doi: 10.1111/tbj.13232. No abstract available.

PMID:
31025516
8.

Cancer Survivorship. Reply.

Shapiro CL.

N Engl J Med. 2019 Apr 4;380(14):1382. doi: 10.1056/NEJMc1900709. No abstract available.

PMID:
30943356
9.

Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor.

Weng SC, Kashida Y, Kulp SK, Wang D, Brueggemeier RW, Shapiro CL, Chen CS.

Mol Cancer Ther. 2019 Apr;18(4):869. doi: 10.1158/1535-7163.MCT-19-0151. No abstract available.

PMID:
30936413
10.

Cancer Survivorship.

Shapiro CL.

N Engl J Med. 2018 Dec 20;379(25):2438-2450. doi: 10.1056/NEJMra1712502. Review. No abstract available.

PMID:
30575480
11.

Osteoporosis and musculoskeletal complications related to therapy of breast cancer.

Suskin J, Shapiro CL.

Gland Surg. 2018 Aug;7(4):411-423. doi: 10.21037/gs.2018.07.05. Review.

12.

Improving Adherence to Endocrine Therapy in Women With HR-Positive Breast Cancer.

Brockway JP, Shapiro CL.

Oncology (Williston Park). 2018 May 15;32(5):235-7, 249.

13.

Reply to L. Kennedy et al.

Shapiro CL, Moriarty JP, Borah B.

J Clin Oncol. 2018 Apr 1;36(10):1052-1053. doi: 10.1200/JCO.2017.77.2749. Epub 2018 Feb 1. No abstract available.

PMID:
29389230
14.

Zoledronic Acid Dosing in Patients With Metastatic Breast Cancer.

Shapiro CL, Himelstein AL.

JAMA Oncol. 2018 Apr 1;4(4):585-586. doi: 10.1001/jamaoncol.2017.0789. No abstract available.

PMID:
29192317
15.

Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain.

Lustberg MB, Orchard TS, Reinbolt R, Andridge R, Pan X, Belury M, Cole R, Logan A, Layman R, Ramaswamy B, Wesolowski R, Berger M, Patterson E, Loprinzi C, Shapiro CL, Yee L.

Breast Cancer Res Treat. 2018 Feb;167(3):709-718. doi: 10.1007/s10549-017-4559-z. Epub 2017 Nov 3.

16.

Cost-Effectiveness Analysis of Monthly Zoledronic Acid, Zoledronic Acid Every 3 Months, and Monthly Denosumab in Women With Breast Cancer and Skeletal Metastases: CALGB 70604 (Alliance).

Shapiro CL, Moriarty JP, Dusetzina S, Himelstein AL, Foster JC, Grubbs SS, Novotny PJ, Borah BJ.

J Clin Oncol. 2017 Dec 10;35(35):3949-3955. doi: 10.1200/JCO.2017.73.7437. Epub 2017 Oct 12.

17.

Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?

Levis BE, Binkley PF, Shapiro CL.

Lancet Oncol. 2017 Aug;18(8):e445-e456. doi: 10.1016/S1470-2045(17)30535-1. Epub 2017 Jul 26. Review.

PMID:
28759384
18.

Management of bone health in postmenopausal women on aromatase inhibitors (AIs): a single health care system experience.

Tremblay D, Patel V, Fifer KM, Caro J, Kolodka O, Mandelli J, Shapiro CL.

Support Care Cancer. 2018 Jan;26(1):197-202. doi: 10.1007/s00520-017-3834-1. Epub 2017 Jul 26.

PMID:
28744736
19.

Randomized phase II trial of fulvestrant alone or in combination with bortezomib in hormone receptor-positive metastatic breast cancer resistant to aromatase inhibitors: a New York Cancer Consortium trial.

Adelson K, Ramaswamy B, Sparano JA, Christos PJ, Wright JJ, Raptis G, Han G, Villalona-Calero M, Ma CX, Hershman D, Baar J, Klein P, Cigler T, Budd GT, Novik Y, Tan AR, Tannenbaum S, Goel A, Levine E, Shapiro CL, Andreopoulou E, Naughton M, Kalinsky K, Waxman S, Germain D.

NPJ Breast Cancer. 2016 Dec 14;2:16037. doi: 10.1038/npjbcancer.2016.37. eCollection 2016.

20.

Discovery of Stromal Regulatory Networks that Suppress Ras-Sensitized Epithelial Cell Proliferation.

Liu H, Dowdle JA, Khurshid S, Sullivan NJ, Bertos N, Rambani K, Mair M, Daniel P, Wheeler E, Tang X, Toth K, Lause M, Harrigan ME, Eiring K, Sullivan C, Sullivan MJ, Chang SW, Srivastava S, Conway JS, Kladney R, McElroy J, Bae S, Lu Y, Tofigh A, Saleh SMI, Fernandez SA, Parvin JD, Coppola V, Macrae ER, Majumder S, Shapiro CL, Yee LD, Ramaswamy B, Hallett M, Ostrowski MC, Park M, Chamberlin HM, Leone G.

Dev Cell. 2017 May 22;41(4):392-407.e6. doi: 10.1016/j.devcel.2017.04.024.

21.

Zoledronic Acid Dosing Interval for Metastatic Cancer-Reply.

Himelstein AL, Loprinzi CL, Shapiro CL.

JAMA. 2017 Apr 11;317(14):1478. doi: 10.1001/jama.2017.2566. No abstract available.

PMID:
28399247
22.

Correction: In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation.

Pichiorri F, Palmieri D, De Luca L, Consiglio J, You J, Rocci A, Talabere T, Piovan C, Lagana A, Cascione L, Guan J, Gasparini P, Balatti V, Nuovo G, Coppola V, Hofmeister CC, Marcucci G, Byrd JC, Volinia S, Shapiro CL, Freitas MA, Croce CM.

J Exp Med. 2017 May 1;214(5):1557. doi: 10.1084/jem.2012095001172017c. Epub 2017 Jan 19. No abstract available.

23.

Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial.

Himelstein AL, Foster JC, Khatcheressian JL, Roberts JD, Seisler DK, Novotny PJ, Qin R, Go RS, Grubbs SS, O'Connor T, Velasco MR Jr, Weckstein D, O'Mara A, Loprinzi CL, Shapiro CL.

JAMA. 2017 Jan 3;317(1):48-58. doi: 10.1001/jama.2016.19425.

24.

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016.

Dittrich C, Kosty M, Jezdic S, Pyle D, Berardi R, Bergh J, El-Saghir N, Lotz JP, Österlund P, Pavlidis N, Purkalne G, Awada A, Banerjee S, Bhatia S, Bogaerts J, Buckner J, Cardoso F, Casali P, Chu E, Close JL, Coiffier B, Connolly R, Coupland S, De Petris L, De Santis M, de Vries EG, Dizon DS, Duff J, Duska LR, Eniu A, Ernstoff M, Felip E, Fey MF, Gilbert J, Girard N, Glaudemans AW, Gopalan PK, Grothey A, Hahn SM, Hanna D, Herold C, Herrstedt J, Homicsko K, Jones DV Jr, Jost L, Keilholz U, Khan S, Kiss A, Köhne CH, Kunstfeld R, Lenz HJ, Lichtman S, Licitra L, Lion T, Litière S, Liu L, Loehrer PJ, Markham MJ, Markman B, Mayerhoefer M, Meran JG, Michielin O, Moser EC, Mountzios G, Moynihan T, Nielsen T, Ohe Y, Öberg K, Palumbo A, Peccatori FA, Pfeilstöcker M, Raut C, Remick SC, Robson M, Rutkowski P, Salgado R, Schapira L, Schernhammer E, Schlumberger M, Schmoll HJ, Schnipper L, Sessa C, Shapiro CL, Steele J, Sternberg CN, Stiefel F, Strasser F, Stupp R, Sullivan R, Tabernero J, Travado L, Verheij M, Voest E, Vokes E, Von Roenn J, Weber JS, Wildiers H, Yarden Y.

ESMO Open. 2016 Sep 29;1(5):e000097. eCollection 2016. Review.

25.

Ready, Fire, Aim: Addressing Issues Associated With Multigene Panel Testing for Cancer Susceptibility.

Boyar SR, Shapiro CL.

Oncology (Williston Park). 2016 Sep 15;30(9):800, 807. No abstract available.

26.

Highlights of Recent Findings on Quality-of-Life Management for Patients With Cancer and Their Survivors.

Shapiro CL.

JAMA Oncol. 2016 Nov 1;2(11):1401-1402. doi: 10.1001/jamaoncol.2016.3620. No abstract available.

PMID:
27608189
27.

Defining High-Quality Palliative Care in Oncology Practice: An American Society of Clinical Oncology/American Academy of Hospice and Palliative Medicine Guidance Statement.

Bickel KE, McNiff K, Buss MK, Kamal A, Lupu D, Abernethy AP, Broder MS, Shapiro CL, Acheson AK, Malin J, Evans T, Krzyzanowska MK.

J Oncol Pract. 2016 Sep;12(9):e828-38. doi: 10.1200/JOP.2016.010686. Epub 2016 Aug 16.

PMID:
27531376
28.

Integrin-linked kinase as a novel molecular switch of the IL-6-NF-κB signaling loop in breast cancer.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Chao MW, Tseng YC, Yang MC, Salunke SB, Sullivan NJ, Chen WC, Zhang J, Teng CM, Fu WM, Sun D, Wicha MS, Shapiro CL, Chen CS.

Carcinogenesis. 2016 Apr;37(4):430-442. doi: 10.1093/carcin/bgw020. Epub 2016 Feb 19.

29.

ReCAP: ASCO Core Curriculum for Cancer Survivorship Education.

Shapiro CL, Jacobsen PB, Henderson T, Hurria A, Nekhlyudov L, Ng A, Surbone A, Mayer DK, Rowland JH, Shapiro CL, Jacobsen PB, Henderson T, Hurria A, Nekhlyudov L, Ng A, Surbone A, Mayer DK, Rowland JH.

J Oncol Pract. 2016 Feb;12(2):145, e108-17. doi: 10.1200/JOP.2015.009449. Epub 2016 Jan 26.

PMID:
26813926
30.

Predictors of duloxetine response in patients with oxaliplatin-induced painful chemotherapy-induced peripheral neuropathy (CIPN): a secondary analysis of randomised controlled trial - CALGB/alliance 170601.

Smith EM, Pang H, Ye C, Cirrincione C, Fleishman S, Paskett ED, Ahles T, Bressler LR, Le-Lindqwister N, Fadul CE, Loprinzi C, Shapiro CL; Alliance for Clinical Trials in Oncology.

Eur J Cancer Care (Engl). 2017 Mar;26(2). doi: 10.1111/ecc.12421. Epub 2015 Nov 25.

31.

Risk factors for anthracycline-associated cardiotoxicity.

Reinbolt RE, Patel R, Pan X, Timmers CD, Pilarski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2016 May;24(5):2173-2180. doi: 10.1007/s00520-015-3008-y. Epub 2015 Nov 12.

32.

Noncatalytic PTEN missense mutation predisposes to organ-selective cancer development in vivo.

Caserta E, Egriboz O, Wang H, Martin C, Koivisto C, Pecót T, Kladney RD, Shen C, Shim KS, Pham T, Karikomi MK, Mauntel MJ, Majumder S, Cuitino MC, Tang X, Srivastava A, Yu L, Wallace J, Mo X, Park M, Fernandez SA, Pilarski R, La Perle KM, Rosol TJ, Coppola V, Castrillon DH, Timmers C, Cohn DE, O'Malley DM, Backes F, Suarez AA, Goodfellow P, Chamberlin HM, Macrae ER, Shapiro CL, Ostrowski MC, Leone G.

Genes Dev. 2015 Aug 15;29(16):1707-20. doi: 10.1101/gad.262568.115.

33.

Function of Integrin-Linked Kinase in Modulating the Stemness of IL-6-Abundant Breast Cancer Cells by Regulating γ-Secretase-Mediated Notch1 Activation in Caveolae.

Hsu EC, Kulp SK, Huang HL, Tu HJ, Salunke SB, Sullivan NJ, Sun D, Wicha MS, Shapiro CL, Chen CS.

Neoplasia. 2015 Jun;17(6):497-508. doi: 10.1016/j.neo.2015.06.001.

34.

Assuring Quality Cancer Survivorship Care: We've Only Just Begun.

Mayer DK, Shapiro CL, Jacobson P, McCabe MS.

Am Soc Clin Oncol Educ Book. 2015:e583-91. doi: 10.14694/EdBook_AM.2015.35.e583. Review.

35.

Association of osteoprotegerin and bone loss after adjuvant chemotherapy in early-stage breast cancer.

Oostra DR, Lustberg MB, Reinbolt RE, Pan X, Wesolowski R, Shapiro CL.

Mol Cell Endocrinol. 2015 Feb 15;402:51-6. doi: 10.1016/j.mce.2014.12.028. Epub 2015 Jan 6.

36.

Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2015 Jul;23(7):2019-24. doi: 10.1007/s00520-014-2556-x. Epub 2014 Dec 18.

37.

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.

Couch FJ, Hart SN, Sharma P, Toland AE, Wang X, Miron P, Olson JE, Godwin AK, Pankratz VS, Olswold C, Slettedahl S, Hallberg E, Guidugli L, Davila JI, Beckmann MW, Janni W, Rack B, Ekici AB, Slamon DJ, Konstantopoulou I, Fostira F, Vratimos A, Fountzilas G, Pelttari LM, Tapper WJ, Durcan L, Cross SS, Pilarski R, Shapiro CL, Klemp J, Yao S, Garber J, Cox A, Brauch H, Ambrosone C, Nevanlinna H, Yannoukakos D, Slager SL, Vachon CM, Eccles DM, Fasching PA.

J Clin Oncol. 2015 Feb 1;33(4):304-11. doi: 10.1200/JCO.2014.57.1414. Epub 2014 Dec 1.

38.

Pluripotent stem cell miRNAs and metastasis in invasive breast cancer.

Volinia S, Nuovo G, Drusco A, Costinean S, Abujarour R, Desponts C, Garofalo M, Baffa R, Aeqilan R, Maharry K, Sana ME, Di Leva G, Gasparini P, Dama P, Marchesini J, Galasso M, Manfrini M, Zerbinati C, Corrà F, Wise T, Wojcik SE, Previati M, Pichiorri F, Zanesi N, Alder H, Palatini J, Huebner KF, Shapiro CL, Negrini M, Vecchione A, Rosenberg AL, Croce CM, Garzon R.

J Natl Cancer Inst. 2014 Oct 11;106(12). pii: dju324. doi: 10.1093/jnci/dju324. Print 2014 Dec. Erratum in: J Natl Cancer Inst. 2014 Nov:106(11):dju373doi:10.1093/jnci/dju373. Garzon, Maria Elena Sana Ramiro [Corrected to Garzon, Ramiro and Sana, Maria Elena].

39.

Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program.

Ko NY, Darnell JS, Calhoun E, Freund KM, Wells KJ, Shapiro CL, Dudley DJ, Patierno SR, Fiscella K, Raich P, Battaglia TA.

J Clin Oncol. 2014 Sep 1;32(25):2758-64. doi: 10.1200/JCO.2013.53.6037. Epub 2014 Jul 28.

40.

AMPK reverses the mesenchymal phenotype of cancer cells by targeting the Akt-MDM2-Foxo3a signaling axis.

Chou CC, Lee KH, Lai IL, Wang D, Mo X, Kulp SK, Shapiro CL, Chen CS.

Cancer Res. 2014 Sep 1;74(17):4783-95. doi: 10.1158/0008-5472.CAN-14-0135. Epub 2014 Jul 3. Erratum in: Cancer Res. 2018 Jun 15;78(12 ):3401.

41.

Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance).

Shulman LN, Berry DA, Cirrincione CT, Becker HP, Perez EA, O'Regan R, Martino S, Shapiro CL, Schneider CJ, Kimmick G, Burstein HJ, Norton L, Muss H, Hudis CA, Winer EP.

J Clin Oncol. 2014 Aug 1;32(22):2311-7. doi: 10.1200/JCO.2013.53.7142. Epub 2014 Jun 16.

42.

A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in HER2 positive metastatic breast cancer.

Zhao M, Pan X, Layman R, Lustberg MB, Mrozek E, Macrae ER, Wesolowski R, Carothers S, Puhalla S, Shapiro CL, Ramaswamy B.

Invest New Drugs. 2014 Dec;32(6):1285-94. doi: 10.1007/s10637-014-0122-5. Epub 2014 Jun 5.

43.

Treatment-related mortality with everolimus in cancer patients.

Wesolowski R, Abdel-Rasoul M, Lustberg M, Paskell M, Shapiro CL, Macrae ER.

Oncologist. 2014 Jun;19(6):661-8. doi: 10.1634/theoncologist.2013-0355. Epub 2014 May 2.

44.

Induction of ATM/ATR pathway combined with Vγ2Vδ2 T cells enhances cytotoxicity of ovarian cancer cells.

Lu J, Das M, Kanji S, Aggarwal R, Joseph M, Ray A, Shapiro CL, Pompili VJ, Das H.

Biochim Biophys Acta. 2014 Jul;1842(7):1071-9. doi: 10.1016/j.bbadis.2014.04.003. Epub 2014 Apr 13.

45.

Phase II trial of neoadjuvant weekly nanoparticle albumin-bound paclitaxel, carboplatin, and biweekly bevacizumab therapy in women with clinical stage II or III HER2-negative breast cancer.

Mrózek E, Layman R, Ramaswamy B, Lustberg M, Vecchione A, Knopp MV, Shapiro CL.

Clin Breast Cancer. 2014 Aug;14(4):228-34. doi: 10.1016/j.clbc.2014.02.005. Epub 2014 Feb 20.

46.

microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers.

Gasparini P, Cascione L, Fassan M, Lovat F, Guler G, Balci S, Irkkan C, Morrison C, Croce CM, Shapiro CL, Huebner K.

Oncotarget. 2014 Mar 15;5(5):1174-84.

47.

Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation.

Gasparini P, Lovat F, Fassan M, Casadei L, Cascione L, Jacob NK, Carasi S, Palmieri D, Costinean S, Shapiro CL, Huebner K, Croce CM.

Proc Natl Acad Sci U S A. 2014 Mar 25;111(12):4536-41. doi: 10.1073/pnas.1402604111. Epub 2014 Mar 10. Erratum in: Proc Natl Acad Sci U S A. 2017 Mar 7;114(10 ):E2065.

48.

Quality improvement in breast cancer project: compliance with antiresorptive agents and changing patterns of drug use.

Borden CP, Shapiro CL, Ramirez MT, Kotur L, Farrar W.

J Natl Compr Canc Netw. 2014 Feb;12 Suppl 1:S33-5.

PMID:
24614050
49.

Heterogeneous atypical cell populations are present in blood of metastatic breast cancer patients.

Lustberg MB, Balasubramanian P, Miller B, Garcia-Villa A, Deighan C, Wu Y, Carothers S, Berger M, Ramaswamy B, Macrae ER, Wesolowski R, Layman RM, Mrozek E, Pan X, Summers TA, Shapiro CL, Chalmers JJ.

Breast Cancer Res. 2014 Mar 6;16(2):R23. doi: 10.1186/bcr3622.

50.

Histone H1 phosphorylation in breast cancer.

Harshman SW, Hoover ME, Huang C, Branson OE, Chaney SB, Cheney CM, Rosol TJ, Shapiro CL, Wysocki VH, Huebner K, Freitas MA.

J Proteome Res. 2014 May 2;13(5):2453-67. doi: 10.1021/pr401248f. Epub 2014 Apr 7.

Supplemental Content

Loading ...
Support Center